中国医药创新促进会

中国医药创新促进会(原名“中国医药工业科研开发促进会”，简称“中国药促会”)，英文名称：China Pharmaceutical Innovation and Research Development Association(PhIRDA)，成立于1988年，是经国家民政部登记注册的非营利性全国性4A级社会组织。

中国药促会秉承“创新、产业化、国际化”的宗旨，以临床需求为导向，长期致力于“产学研用资”紧密结合，促进医药行业创新发展，已经成为集医药创新研发型企业、科研机构、临床研究机构、创新服务机构和医药投资机构所组成的医药创新产业化促进平台，目前有会员单位170家。中国药促会已成立了药物研发、药物临床试验研究、医药政策、医药创新投资、创新研发服务、心血管药物临床研究、国际创新药物监管、抗肿瘤药物临床研究、脑神经药物临床研究、糖尿病与代谢性疾病药物临床研究、医药数字化及创新疗法、创新医疗器械专业委员会，形成了以创新为核心，以促进创新为目标的涵盖药物研发、生产、使用以及投融资的全链条组织构架，并作为国际药品制造商协会联合会(IFPMA)的成员继续拓展国际交流渠道。

中国药促会工作内容主要包括：一是开展医药政策研究，为我国医改事业、完善药物政策和医药产业发展建言献策;二是通过举办各种论坛、发布会、大型会议等活动，促进会员单位乃至整个医药产业的相互交流、创新发展;三是通过与国内外医药行业协会、企业、科研机构和外国驻华使馆合作，推动国际医药产业的多方位、多维度合作交流，为会员单位搭建国际交流平台;四是践行国家创新驱动发展战略指导精神，为会员单位拓宽医药创新投融资渠道、搭建合作平台，推动社会资本加大对初创及研发型企业自主创新项目的投入，营造更有吸引力的医药创新投资环境;五是为会员单位提供医药信息搜集、整理、评价服务，包括编辑每日《医药信息简报》、每周《国际医药产业发展动态与研发信息简报》等内部电子刊物以及中国药促会官方网站、微信公众号等服务平台。

中国药促会将围绕办会宗旨，不断拓展服务内涵和外延，做好政府与会员企业的桥梁和纽带，维护会员合法权益，加强行业自律，推动我国医药产业的创新和可持续发展，为加快我国经济社会发展、保障人民群众健康不断做出贡献!

Brief Introduction of PhIRDA

Founded in 1988, China Pharmaceutical Innovation and Research Development Association (PhIRDA), formerly named China Pharmaceutical Industry Research and Development Association, is registered as a non-profit 4A social organization by the Ministry of Civil Affairs of China at national level.

PhIRDA has been exerting great effort on “academia-industry-investment collaboration”, which centers on the principle of “innovation, industrialization, internationalization”, and persists in innovation to achieve unmet clinical requirements. As a platform facilitating the industrialization of pharmaceutical innovation, PhIRDA currently has 170 members mainly consists of pharmaceutical R&D enterprises, research institutions, clinical institutions, R&D Services companies and investment institutions focusing on pharmaceutical innovation. Moreover, PhIRDA has established the following Specialty Committees: Drug R&D, Clinical Trial Research, Medicinal Policy, Pharmaceutical Innovation Investment and Innovation R&D Services, Clinical Research on Cardiovascular Drugs, International Regulatory Science, Clinical Research on Oncology Drugs, Clinical Research on Cranial Nerve Drugs, Ethics and Business Compliance, Clinical Research on Diabetes and Metabolic Disease Drugs, Digital Medicine and Innovative Therapy, and Innovative Medical Devices, forming a fully functional organization structure focusing on innovation, aiming to promote the development of innovation, covering the whole industrial chain, including drug R&D, manufacturing, using, investment and capital market. PhIRDA is also a member of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to continuously broaden channels of international collaboration.

Major work of PhIRDA includes: first, to conduct policy researches, propose valuable suggestions on healthcare reform and the development of pharmaceutical industry; second, to promote communication and innovative development of our members and even the whole pharmaceutical industry through forums, press-conferences, summits, etc.; third, to make efforts to establish an international exchange platform for our members through cooperation with foreign embassies and foreign associations to stimulate comprehensive communication between China and foreign countries in pharmaceutical field; fourth, to practice the guiding spirits of national innovation-driven development strategy, to broaden the investment and financing channels of pharmaceutical innovation, to build the cooperation platform for our members, and to promote social capitals to pay more attention on investment in innovative projects of start-up and R&D enterprises to create a more attractive environment of pharmaceutical innovation and investment; fifth, to improve the website and WeChat official account of PhIRDA and provide collecting, arranging, revising service of pharmaceutical information, which includes the following internal e-magazines such as the daily Pharmaceutical Information Brief, the weekly International Pharmaceutical Development Tendency and Research Information Brief.

PhIRDA will center on our principle, continuously expand services, build a bridge between the government and our members, maintain legitimate rights and interests of members, strengthen self-discipline, promote healthy development of Chinese pharmaceutical industry, making constant contributions to the greater economic development of the country and public health.